Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Plus Dacarbazine in Japanese Patients With Melanoma
NCT01681212Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Surviving at 1 Year. Started Oct 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01681212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01681212.